ResearcherAalborg University HospitalActive in the last 2 years
Stine Dam Henriksen
Matched on ORCID iD 0000-0003-0286-397X; OpenAlex author ID A5017733773. Sources: ClinicalTrials.gov.
Their work
- Papers
- 13 (first author 1, last author 2)
- Trials
- 1 (principal investigator on 1)
- Grants
- 0
- Labs led
- 1
- Collaborators
- 15
2013: 1 trial · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: none · 2019: 1 paper · 2020: none · 2021: 3 papers · 2022: none · 2023: 3 papers · 2024: 1 paper · 2025: 1 paper
Papers 13
- Promoter hypermethylation of SFRP1 is an allele fraction-dependent prognostic biomarker in metastatic pancreatic ductal adenocarcinoma. Last author DOI 10.3389/fonc.2025.1568386↗
- Prediction of pancreatic cancer risk in patients with new-onset diabetes using a machine learning approach based on routine biochemical parameters. Co-author DOI 10.1016/j.cmpb.2023.107965↗
- Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with stage III or IV pancreatic ductal adenocar… Co-author DOI 10.1016/j.pan.2023.05.003↗
- Risk of pancreatic cancer in people with new-onset diabetes: A Danish nationwide population-based cohort study. Co-author DOI 10.1016/j.pan.2023.07.001↗
- Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with localized pancreatic ductal adenocarcinoma. Last author DOI 10.3389/fonc.2023.1211292↗
- Cell-free DNA promoter hypermethylation as a diagnostic marker for pancreatic ductal adenocarcinoma - An external validation study. Co-author DOI 10.1016/j.pan.2021.05.003↗
- Validation of SFRP1 Promoter Hypermethylation in Plasma as a Prognostic Marker for Survival and Gemcitabine Effectiveness in Patients with Stage IV Pancreatic … First author DOI 10.3390/cancers13225717↗
- Cell-Free DNA Methylation as Blood-Based Biomarkers for Pancreatic Adenocarcinoma-A Literature Update. Co-author DOI 10.3390/epigenomes5020008↗
- Treatment of locally advanced pancreatic cancer with irreversible electroporation - a Danish single center study of safety and feasibility. Co-author DOI 10.1080/00365521.2019.1575465↗
- Promoter hypermethylation in plasma-derived cell-free DNA as a prognostic marker for pancreatic adenocarcinoma staging. Co-author DOI 10.1002/ijc.31024↗
- Cell-free DNA promoter hypermethylation in plasma as a predictive marker for survival of patients with pancreatic adenocarcinoma. Co-author DOI 10.18632/oncotarget.21397↗
- Cell-free DNA promoter hypermethylation in plasma as a diagnostic marker for pancreatic adenocarcinoma. Co-author DOI 10.1186/s13148-016-0286-2↗
- DNA Hypermethylation as a Blood-Based Marker for Pancreatic Cancer: A Literature Review. Co-author DOI 10.1097/mpa.0000000000000487↗
Trials 1
- DNA Promoter Hypermethylation as a Blood Based Maker for Pancreatic Cancer Principal investigator NCT02079363↗
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Ole Thorlacius‐Ussing · 11 shared papers, 1 shared trial, 2013–2025 · strength 1.59
- Paper Cell-Free DNA Methylation as Blood-Based Biomarkers for Pancreatic Adenocarcinoma-A Literature Update. DOI 10.3390/epigenomes5020008↗
- Paper Promoter hypermethylation of SFRP1 is an allele fraction-dependent prognostic biomarker in metastatic pancreatic ductal… DOI 10.3389/fonc.2025.1568386↗
- Paper Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with st… DOI 10.1016/j.pan.2023.05.003↗
- Benjamin Emil Stubbe · 5 shared papers, 2021–2025 · strength 0.81
- Paper Promoter hypermethylation of SFRP1 is an allele fraction-dependent prognostic biomarker in metastatic pancreatic ductal… DOI 10.3389/fonc.2025.1568386↗
- Paper Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with st… DOI 10.1016/j.pan.2023.05.003↗
- Paper Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with lo… DOI 10.3389/fonc.2023.1211292↗
- Julia Sidenius Johansen · 4 shared papers, 2021–2025 · strength 0.67
- Paper Promoter hypermethylation of SFRP1 is an allele fraction-dependent prognostic biomarker in metastatic pancreatic ductal… DOI 10.3389/fonc.2025.1568386↗
- Paper Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with st… DOI 10.1016/j.pan.2023.05.003↗
- Paper Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with lo… DOI 10.3389/fonc.2023.1211292↗
- Carsten Palnæs Hansen · 4 shared papers, 2021–2025 · strength 0.67
- Paper Promoter hypermethylation of SFRP1 is an allele fraction-dependent prognostic biomarker in metastatic pancreatic ductal… DOI 10.3389/fonc.2025.1568386↗
- Paper Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with st… DOI 10.1016/j.pan.2023.05.003↗
- Paper Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with lo… DOI 10.3389/fonc.2023.1211292↗
- Asbjørn Mohr Drewes · 3 shared papers, 2016–2024 · strength 0.54
- Paper Prediction of pancreatic cancer risk in patients with new-onset diabetes using a machine learning approach based on rou… DOI 10.1016/j.cmpb.2023.107965↗
- Paper Risk of pancreatic cancer in people with new-onset diabetes: A Danish nationwide population-based cohort study. DOI 10.1016/j.pan.2023.07.001↗
- Paper Cell-free DNA promoter hypermethylation in plasma as a diagnostic marker for pancreatic adenocarcinoma. DOI 10.1186/s13148-016-0286-2↗
- Simon Lebech Cichosz · 2 shared papers, 2023–2024 · strength 0.48
- Paper Prediction of pancreatic cancer risk in patients with new-onset diabetes using a machine learning approach based on rou… DOI 10.1016/j.cmpb.2023.107965↗
- Paper Risk of pancreatic cancer in people with new-onset diabetes: A Danish nationwide population-based cohort study. DOI 10.1016/j.pan.2023.07.001↗
- Morten Hasselstrøm Jensen · 2 shared papers, 2023–2024 · strength 0.48
- Paper Prediction of pancreatic cancer risk in patients with new-onset diabetes using a machine learning approach based on rou… DOI 10.1016/j.cmpb.2023.107965↗
- Paper Risk of pancreatic cancer in people with new-onset diabetes: A Danish nationwide population-based cohort study. DOI 10.1016/j.pan.2023.07.001↗
- Søren Schou Olesen · 2 shared papers, 2023–2024 · strength 0.48
- Paper Prediction of pancreatic cancer risk in patients with new-onset diabetes using a machine learning approach based on rou… DOI 10.1016/j.cmpb.2023.107965↗
- Paper Risk of pancreatic cancer in people with new-onset diabetes: A Danish nationwide population-based cohort study. DOI 10.1016/j.pan.2023.07.001↗
- Astrid Zedlitz Johansen · 2 shared papers, 2023–2025 · strength 0.36
- Paper Promoter hypermethylation of SFRP1 is an allele fraction-dependent prognostic biomarker in metastatic pancreatic ductal… DOI 10.3389/fonc.2025.1568386↗
- Paper Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with lo… DOI 10.3389/fonc.2023.1211292↗
- Lars Henrik Jensen · 1 shared paper, 2025 · strength 0.19
- Louise S. Rasmussen · 1 shared paper, 2025 · strength 0.19
- Per Pfeiffer · 1 shared paper, 2025 · strength 0.19
- Inna Markovna Chen · 1 shared paper, 2025 · strength 0.19
- Rasmus Virenfeldt Flak · 1 shared paper, 2019 · strength 0.10
- Mogens Tornby Stender · 1 shared paper, 2019 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.